SCHEMBL461562

SCHEMBL461562

NNN1C(=O)C=CC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL175725 0.73 MGLL (0.42)
SCHEMBL515246 0.71
SCHEMBL16129944 0.69
SCHEMBL2571475 0.69
SCHEMBL2922210 0.69
SCHEMBL18282001 0.69
SCHEMBL8556424 0.67 GAA (0.32)
SCHEMBL9463988 0.66 MGLL (0.37)
SCHEMBL9809715 0.66 GAA (0.31)
SCHEMBL5053834 0.66 GAA (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190023743-A1 METHODS AND COMPOSITIONS FOR MODULATING DRUG-POLYMER ARCHITECTURE, PHARMACOKINETICS AND BIODISTRIBUTION DUKE UNIVERSITY 2019-01-24 US claimed
US-20140024600-A1 METHODS AND COMPOSITIONS FOR MODULATING DRUG-POLYMER ARCHITECTURE, PHARMACOKINETICS AND BIODISTRIBUTION DUKE UNIVERSITY (US) 2014-01-23 US claimed
US-20110207673-A1 METHODS AND COMPOSITIONS FOR MODULATING DRUG-POLYMER ARCHITECTURE, PHARMACOKINETICS AND BIODISTRIBUTION DUKE UNIVERSITY 2011-08-25 US claimed
WO-2009067584-A1 METHODS AND COMPOSITIONS FOR MODULATING DRUG-POLYMER ARCHITECTURE, PHARMACOKINETICS AND BIODISTRIBUTION DUKE UNIVERSITY (US) 2009-05-28 WO claimed
US-20250302981-A1 NOVEL USE OF ANTICANCER AGENT PRODRUG CONJUGATE UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION (KR) 2025-10-02 US disclosed
WO-2025098478-A1 WHOLE-PROCESS TARGETING POLYPEPTIDE, PHARMACEUTICAL COMPLEX THEREOF, DRUG DELIVERY SYSTEM AND USE THEREOF 复旦大学 2025-05-15 WO disclosed
WO-2025053315-A1 METHOD FOR RECOVERING AND REMOVING PALLADIUM IN PREPARATION OF ANTICANCER AGENT PRODRUG CONJUGATE 파로스젠 주식회사 2025-03-13 WO disclosed
US-11622990-B2 VAP polypeptide and use thereof in preparation of drug for targeted diagnosis and treatment of tumor FUDAN UNIVERSITY (CN) 2023-04-11 US disclosed
US-11572373-B2 Maytansinoid-based drug delivery systems LADRX CORPORATION (US) 2023-02-07 US disclosed
CN-109265512-B Preparation method of protein conjugate based on pyridine dicarbaldehyde 清华大学 2021-06-11 CN disclosed
US-20200385403-A1 MAYTANSINOID-BASED DRUG DELIVERY SYSTEMS LADRX CORPORATION 2020-12-10 US disclosed
US-20190314446-A1 VAP POLYPEPTIDE AND USE THEREOF IN PREPARATION OF DRUG FOR TARGETED DIAGNOSIS AND TREATMENT OF TUMOR FUDAN UNIVERSITY (CN) 2019-10-17 US disclosed
WO-2005115477-A2 NON-NATURAL RIBONUCLEASE CONJUGATES AS CYTOTOXIC AGENTS QUINTESSENCE BIOSCIENCES, INC. (US) 2005-12-08 WO disclosed
US-20050261232-A1 Non-natural ribonuclease conjugates as cytotoxic agents QUINTESSENCE BIOSCIENCES, INC. (US) 2005-11-24 US disclosed
US-20050002942-A1 Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates ENDOCYTE, INC. 2005-01-06 US disclosed
CN-1509166-A Liposome composition for improved intracellular delivery of therapeutic agent 2004-06-30 CN disclosed
EP-1019722-B1 POLYMERIC FLUOROPHORES ENHANCED BY MOIETIES PROVIDING A HYDROPHOBIC AND CONFORMATIONALLY RESTRICTIVE MICROENVIRONMENT ABBOTT LAB (US) 2003-04-09 EP disclosed
EP-1019722-A1 POLYMERIC FLUOROPHORES ENHANCED BY MOIETIES PROVIDING A HYDROPHOBIC AND CONFORMATIONALLY RESTRICTIVE MICROENVIRONMENT Abbott Laboratories (US) 2000-07-19 EP disclosed
US-5994143-A FLUORESCENT CONJUGATES SUITABLE FOR USE IN FLOW CYTOMETRY AND OTHER BIOLOGICAL APPLICATIONS; THE FLUORESCENT CONJUGATES COMPRISE AN ANTIBODY HAVING A POLYMERIC DYE BOUND THERETO ABBOTT LABORATORIES (US) 1999-11-30 US disclosed
WO-1997028447-A1 POLYMERIC FLUOROPHORES ENHANCED BY MOIETIES PROVIDING A HYDROPHOBIC AND CONFORMATIONALLY RESTRICTIVE MICROENVIRONMENT ABBOTT LABORATORIES (US) 1997-08-07 WO disclosed